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Abstract Relaxin is a naturally occurring human peptide
initially identified as a reproductive hormone. More
recently, relaxin has been shown to play a key role in the
maternal hemodynamic and renal adjustments that accom-
modate pregnancy. An understanding of these physiologic
effects has led to the evaluation of relaxin as a pharmaco-
logic agent for the treatment of patients with acute heart
failure. Preliminary results have been encouraging. In
addition, the other known biologic properties of relaxin,
including anti-inflammatory effects, extracellular matrix
remodeling effects, and angiogenic and anti-ischemic
effects, all may play a role in potential benefits of relaxin
therapy. Ongoing, large-scale clinical testing will provide
additional insights into the potential role of relaxin in the
treatment of heart failure.
Keywords Relaxin . Acute heart failure . Congestive heart
failure . Vasodilation . Dyspnea . Pharmacologic therapy
Introduction
Hospitalizations for acute heart failure (AHF) have tradi-
tionally been viewed as resulting from salt and fluid
accumulation in patients with chronic heart failure. Diuretic
therapy has evolved to be, and is still considered, the best
intervention for acute symptom relief, despite the growing
recognition of its limitations and the absence of compelling
clinical data to support its use [1]. The significant
contribution of vascular dysfunction to the pathophysiology
of AHF has more recently been recognized [2•]. These
patients are characterized by preserved or elevated systolic
blood pressure and increased vascular stiffness with less
fluid overload. They are more likely to be elderly and
female. Large-scale registry studies suggest that patients
with vascular dysfunction causing AHF represent the
majority of patients, and that this may have been underap-
preciated during previous development of new therapies.
An even more comprehensive and integrated disease
model would now include consideration of cardiac, renal,
vascular, neurohormonal, inflammatory, ischemic, and
fibrotic mechanisms [2•, 3]. Perhaps this growing under-
standing of disease complexity in AHF may lead to the
development of new interventions that benefit these
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patients. In particular, the ability to identify different
subgroups of patients with AHF may enable therapies that
target the underlying pathophysiology, with the potential
for greater therapeutic success.
The peptide hormone relaxin has a long history as a
reproductive hormone since its discovery in 1926 [4, 5]. In
women, circulatory concentrations of relaxin rise in the first
trimester, coincident with notable cardiovascular and renal
adjustments of the maternal circulation during pregnancy
[6••]. These adjustments include systemic vasodilation to
meet the increased nutritional demands of the growing fetus
and increased renal function to accommodate the height-
ened requirements for renal clearance of metabolic wastes.
These adaptations include a 20% increase in cardiac output,
30% decrease in systemic vascular resistance, 30% increase
in global arterial compliance, and 45% increase in renal
blood flow [6••], [7, 8]. Clinical and nonclinical studies
using relaxin have recapitulated these effects in males, as
well as females, leading to a growing recognition that the
physiologic effects of relaxin may be pharmacologically
useful in modulating cardiovascular and renal function.
This review focuses on the major biological properties of
relaxin, that is, hemodynamic and renal, and their potential
role in heart failure therapy. Clinical trials of relaxin in
patients with heart failure have begun to generate encour-
aging results due to these biological properties [9••, 10••].
Evidence of relaxin pharmacology was also apparent in
early clinical studies in non-heart failure indications. Other
biologic properties of relaxin, including its antifibrotic,
anti-inflammatory, and anti-ischemic effects, are also
described, as they could potentially address the multiple
facets of the pathophysiology of heart failure.
Mechanisms of Action
Decades of cumulative biological, pharmacologic, and
clinical experimentation have led to our current understand-
ing of the biology of relaxin, depicted in Fig. 1 [6••, 11–
13••, 14]. The major effects of relaxin, consisting of the
modulation of systemic and renal vascular tone, are
mediated by multiple mechanisms (Fig. 1). Amongst them,
its interaction with the endothelin system appears to have a
pivotal role. This system is responsible, at least in part, for
physiological regulation of basal vascular tone [15, 16].
Endothelin-1 (ET-1) is synthesized by vascular endothelial
cells and acts through binding to specific endothelin-A (ET-
A) and Endothelin-B (ET-B) receptors. ET-A receptors are
located on vascular smooth muscle cells and mediate
vasoconstriction. ET-B receptors on endothelial cells are
vasodilatory, whereas those on smooth muscle cells are
vasoconstrictive. Normal tone results from the balance
between ET-1 stimulation of ET-A and ET-B receptors [16].
In heart failure, pathologically elevated levels of endothelin
cause arterial and venous vasoconstriction, contribute to
symptoms, and are associated with adverse outcomes [17–
19]. Furthermore, in human heart failure, there is altered
expression of endothelin receptors with increased ET-A
receptor density and decreased ET-B receptor density [20].
Relaxin activity is initiated by binding to its cognate
receptor, which has been localized in the systemic and renal
vasculature, as well as in the tubules of the kidney [21].
The close proximity of the relaxin receptor to components
of the endothelin pathway in these anatomical locations is
consistent with the perceived interaction of the two
endogenously occurring systems. Furthermore, isolated
Fig. 1 Biology of relaxin and potential beneficial effects in heart
failure. Heart failure is a cardiac-renal-vascular-neurohormonal-
inflammatory-ischemic-fibrotic disorder. Human data indicate that
relaxin relieves systemic and renal vasoconstriction and increases
vascular compliance, including normalization of high BP, ↓ PCWP, ↑
CO, ↑ renal blood flow, natriuresis, and decongestion. Animal
pharmacology data indicate that relaxin has anti-inflammatory and
cardiac protection effects, including ↓ myocardial ischemia, ↓
reperfusion injury, ↑ wound healing, ↓ ventricular fibrosis. BP—
blood pressure; CO—cardiac output; ET—endothelin; MMP—matrix
metalloproteinase; NO—nitric oxide; NOS—nitric oxide synthase;
PCWP—pulmonary capillary wedge pressure; TGF—transforming
growth factor; TNF—tumor necrosis factor; VEGF—vascular endo-
thelial growth factor
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vessels ex vivo respond to relaxin exposure by vasodilation,
indicating that the relaxin receptor and the downstream
mechanisms mediating dilation are located within the
vessels themselves. Relaxin binding to its receptor results
in activation of the ET-B receptor on endothelial cells,
shifting the balance of vascular tone toward vasodilation
[22–24]. Systemically, relaxin appears to directly stimulate
expression of the ET-B receptor on endothelial cells, whereas
stimulation of ET synthesis, resulting in increased engage-
ment and activation of the endothelial ET-B receptor, appears
to be the pathway in the kidney. The two pathways converge
in increased local nitric oxide production. Although not as
well understood, relaxin may also activate the ET-B receptor
in the tubules of the kidney, thereby inhibiting the Na/K
ATPase and facilitating sodium and water excretion.
Clinical Data on Vasodilation
Extensive clinical data document the vasodilatory effects of
relaxin. In a dose-ranging study of relaxin given to 16
patients with stable heart failure, systemic hemodynamics
were directly measured by Swan-Ganz catheterization [9••].
Vasodilation was documented as a decrease in pulmonary
capillary wedge pressure (PCWP) and systemic vascular
resistance (SVR), and an increase in cardiac output (CO).
Doses evaluated ranged from 10 to 960 μg/kg/d for 24 h.
Trends in improvement in a number of hemodynamic
parameters were observed during dosing and for several hours
thereafter. Doses of relaxin in the range of 10 to 100 μg/kg/d
appeared to have a more pronounced effect than higher doses
on right atrial pressure, pulmonary artery pressure, PCWP, and
NT-pro BNP, whereas the effects on cardiac index and SVR
were more modest and appeared somewhat greater at
higher doses. For example, the mean changes from
baseline in PCWP at 30, 100, 480, and 960 μg/kg/d
were −5.0 ±2.6 mmHg, −3.5 ±3.7 mmHg, 0.33±
2.6 mmHg, and −0.17±2.7 mmHg, respectively. No
consistent changes in heart rate or blood pressure were
observed either during dosing or postdosing.
The different dose responses observed for the hemody-
namic parameters may be explained by imbalances in
baseline hemodynamic status of the dose groups or may be
due to random variability in a small pilot study. However,
certain biological effects of relaxin are known to follow a
U-shaped dose-response curve [25–27]. Alternatively,
counter-regulatory neurohormonal mechanisms may have
been stimulated at higher relaxin doses, thus overpowering
the salutary responses observed at the lower doses. An
intriguing alternative explanation may be that doses in the
lower range produce more venous vasodilation (decrease in
PCWP without change in CO/CI), whereas higher doses
may produce more arterial vasodilation. Additional well-
controlled hemodynamic studies will be required to provide
further insight into this pattern.
Based on these hemodynamic effects, relaxin was
subsequently tested in the Pre-RELAX-AHF Phase II trial.
This trial was designed to assess drug effects on multiple end
points, including symptoms, signs, and short-term outcomes
in patients with AHF. A total of 234 patients hospitalized
with dyspnea due to AHF were randomly assigned to receive
placebo or one of four active doses of relaxin (10, 30, 100, or
250 μg/kg/d) for 48 h. A clear vasodilatory effect of relaxin
was seen in the greater reduction of blood pressure in
relaxin-treated patients compared with those receiving
placebo, despite greater use of diuretics and intravenous
nitroglycerin in the placebo group [10••].
The effects of relaxin on blood pressure corresponded
directly to the relief of dyspnea, which were rapid and
clinically meaningful, consistent with effects seen with
other vasodilators. However, unlike other vasodilators, the
effects of relaxin were sustained to day 14 (Table 1). It is
possible that the impact of relaxin on both vasodilation and
natriuresis/diuresis (see section below) may have led to
more complete resolution of congestion, thereby fostering a
prolonged amelioration of symptoms. Patients treated with
relaxin also demonstrated trends toward greater resolution
of congestion, measured as improvements in edema and
pulmonary rales, as well as a shorter length of index
hospital stay, and improved morbidity and mortality.
Greater decongestion in patients with AHF has previously
been associated with improved prognosis during the first 2
to 6 months following discharge [28, 29]. In addition, the
proportion of patients demonstrating inhospital worsening
heart failure during the first 5 days (defined as an increase
in symptoms requiring intervention) was lower in the
groups receiving relaxin compared with those receiving
placebo. Early recurrence or worsening of heart failure has
been associated with poor intermediate-term prognosis and
may reflect persistence of underlying pathophysiologic
mechanisms in AHF, including neurohormonal, inflamma-
tory, and ischemic mechanisms [30].
The dose in Pre-RELAX-AHF that was associated with
the greatest benefit was 30 μg/kg/d; this dose is being
tested further in the ongoing Phase III RELAX-AHF study.
Interestingly, in Pre-RELAX-AHF, a greater vasodilatory
effect and corresponding improvement in dyspnea [31]
were observed in patients presenting with higher baseline
blood pressure. This is consistent with observations made
in nonclinical studies, in which hemodynamic effects of
relaxin were proportional to the extent of baseline abnor-
mality [27]. Also, in a clinical trial of 239 patients with
progressive systemic sclerosis (PSS), relaxin caused small
but statistically significant reductions in blood pressure of
approximately 5 mmHg, consistent with changes observed
in pregnancy, during 6 months of continuous therapy [13••].
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A greater degree of blood pressure reduction (15–
20 mmHg) was observed in the subset of patients who
were hypertensive at baseline compared with those who
were normotensive.
Clinical Data on Renal Effects
A number of clinical trials have suggested that relaxin
stimulates increases in renal blood flow (RBF), consistent
with a large body of nonclinical research indicating that
relaxin causes vasodilation of the renal vasculature. A study
of relaxin administered to healthy volunteers directly
measured its effects on RBF, glomerular filtration rate
(GFR), and electrolyte clearance [32]. Eleven subjects
received 5-hour infusions of relaxin that led to serum
concentrations approximating those seen in pregnancy, and
GFR and RBF were measured using inulin and para-
aminohippurate, respectively.
Consistent with the effects of endogenously circulating
relaxin in pregnancy, relaxin administration was associated
with a significant 47% increase in RBF, with evidence of an
increase within 30 min of relaxin infusion. No increase in
GFR was measured. Relaxin-stimulated increases in clear-
ance and urinary excretion of sodium were also measured,
consistent with nonclinical models [33].
In the Pre-RELAX-AHF heart failure study, there were
consistent trends toward increased weight loss in the relaxin
treatment groups that were measured at multiple time
points, including 24 and 48 h of dosing and at 5 days and
at 14 days postdosing [10••]. Although statistical signifi-
cance was seen only at some time points, the overall trend
supports the hypothesis that relaxin may have had a
natriuretic/diuretic effect in these heart failure patients.
Although the study examining relaxin’s renal pharma-
cology did not show that an increase in GFR accompanied
the elevation in RBF [32], other clinical data do suggest
that relaxin may be able to modulate GFR. In the study of
relaxin in patients with systemic sclerosis, there was a
statistically significant 10% to 15% increase in the
predicted creatinine clearance associated with relaxin
administration throughout the 6-month treatment period,
suggesting an increase in GFR [13••, 34].
Similarly, in 16 patients with stable AHF, decreases in
serum creatinine and BUN (blood urea nitrogen) were
observed during the 24-hour relaxin infusion and for an
additional 24 h thereafter [9••]. At higher doses of drug,
however, 1 week after completion of dosing, creatinine and
BUN levels had returned to levels that were higher than
baseline. There were no clinical consequences associated
with these observed laboratory value changes.
In the Pre-RELAX-AHF study, no consistent changes in
serum creatinine were observed during the relaxin infusion
in AHF patients [10••]. It is possible that other medications
may have interfered with a relaxin effect or that a difference
in the underlying renal biology in these patients affects the
response to relaxin. At the highest dose of relaxin tested,
postdosing trends toward increased creatinine levels were
observed. There were no clinical correlations of these
laboratory value changes.
Anti-inflammatory Effects and Prevention
of Reperfusion Injury
Inflammation appears to play a pivotal role in the pathogen-
esis of AHF and its poor prognosis [3, 30]. Animal models
have provided data that indicate that relaxin, whose receptors
are localized in the heart [35–37], may have anti-
inflammatory properties and protective effects against reper-
fusion injury. Relaxin inhibits histamine release by mast cells
in rat and guinea pig models of inflammation [38]. It also
inhibits the influx of neutrophils into injured organs [39] and
decreases the release of tumor necrosis factor (TNF)-α in
response to adjuvant [40] and the release of interleukin (IL)-
1, IL-6, and TNF-α in response to endotoxin [41]. These
anti-inflammatory effects may contribute to the protection
against cardiac reperfusion injury seen with relaxin therapy
in rodent [42, 43] and swine models [44, 45]. In a recent
study in a swine model [45], relaxin administration upon
reperfusion following 30 min of ischemia inhibited plasma
histamine levels, cardiac histamine content, and cardiac mast
cell degranulation. Attendant with these effects, relaxin
inhibited oxidative cardiac tissue injury and the occurrence
of severe ventricular arrhythmias, both consequences of
reperfusion-induced inflammation. Because cardiac arrhyth-
mias contribute to mortality following myocardial infarction,
these findings are of potential significance.
Extracellular Matrix Remodeling Effects
Relaxin has demonstrated the ability to modify extracellular
matrix deposition and turnover in multiple animal models.
Relaxin, infused for as short a period as 2 to 3 days in rats,
has been shown to increase global arterial compliance,
coincident with an increase in cardiac output and decrease
in SVR [46] and consistent with its role in pregnancy [27].
The increase in compliance studied in an ex vivo model
showed a relaxin-mediated increase in compliance inde-
pendent of smooth muscle-mediated changes in tone,
suggesting that alterations in the extracellular matrix of
the vessel wall contributed to increased compliance.
Systemic arterial compliance makes an important con-
tribution to cardiac afterload, and thus, is a significant
determinant of left ventricular work. Previous studies have
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suggested that arterial compliance may be reduced in
patients with congestive heart failure. The ability of relaxin
to increase arterial compliance through vasodilatory and
antifibrotic effects may contribute to its beneficial effects in
heart failure and warrant further investigation [47, 48].
Male relaxin-deficient mice demonstrate an age-related
progression of cardiac fibrosis. Treatment for 2 weeks with
relaxin of established cardiac fibrosis in these mice reduced
collagen deposition [37]. Infusion for 14 days of relaxin
reversed cardiac fibrosis in transgenic animals overexpress-
ing β2 adrenergic receptors, which eventually develop
heart failure [37]. In the spontaneously hypertensive rat
model, relaxin therapy significantly decreased collagen
content in the myocardium of the left ventricle, but not
the unaffected chambers of the heart [49]. In addition,
relaxin has shown similar antifibrotic effects in animal
models of renal and pulmonary fibrosis [50–52].
Angiogenesis, Anti-ischemic Effects
Ischemic heart disease is a common underlying cause of heart
failure. In fact, concurrent ischemia as evidenced by detect-
able levels of troponin identifies a group of patients with AHF
who are at particularly high risk for morbidity and mortality
[53]. In the Pre-RELAX-AHF study [10], a post-hoc
exploratory analysis suggested that patients with detectable
troponin at baseline derived the most benefit from relaxin
therapy with respect to longer-term morbidity and mortality
(Data on File, Corthera, Inc.). Relaxin’s angiogenic proper-
ties were demonstrated using a model of chronic myocardial
infarction in rats [54]. Systemic infusion of relaxin potenti-
ated the increase in basic fibroblast growth factor (bFGF)
mRNA and protein at 7 and 21 days in the peri-infarct region
being expressed by myocytes and fibroblasts. Similar infu-
sions in sham-operated rats showed no change in bFGF or
vascular endothelial growth factor expression in
corresponding regions of the left ventricle or in the right
ventricle. The increase in the number of thin-walled, collateral
vessels lacking smooth muscle was correspondingly potenti-
ated in the peri-infarct region by systemic relaxin administra-
tion. These proangiogenic and anti-ischemic effects, coupled
with the anti-reperfusion injury effects described above, could
potentially play a beneficial role in patients with AHF.
Conclusions
Relaxin is a naturally occurring peptide hormone first
identified for its role in reproduction and now understood to
play a central role in hemodynamic, renal, and other
physiologic and pathologic processes. An appreciation of
its hemodynamic and renal physiologic effects has led to its
evaluation as a potential treatment of AHF with encouraging
results. These results can be directly understood in the
context of the known biology of relaxin, including favorable
effects on multiple mechanisms ranging from central
hemodynamics to kidney function, myocardial ischemia,
and systemic inflammation (Table 2). Further evidence of
therapeutic benefit, however, is still needed from large
multicenter trials such as the ongoing RELAX-AHF, a
phase III study of relaxin in patients hospitalized with AHF.
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